ResMed Inc. (RMD)
| Market Cap | 27.82B |
| Revenue (ttm) | 4.58B |
| Net Income (ttm) | 958.38M |
| Shares Out | 146.91M |
| EPS (ttm) | 6.51 |
| PE Ratio | 29.09 |
| Forward PE | 22.22 |
| Dividend | $1.92 (1.01%) |
| Ex-Dividend Date | May 8, 2024 |
| Volume | 728,083 |
| Open | 187.50 |
| Previous Close | 186.94 |
| Day's Range | 186.75 - 189.94 |
| 52-Week Range | 132.24 - 229.97 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 213.67 (+12.84%) |
| Earnings Date | Aug 1, 2024 |
About RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics... [Read more]
Financial Performance
In 2023, ResMed's revenue was $4.22 billion, an increase of 18.02% compared to the previous year's $3.58 billion. Earnings were $897.56 million, an increase of 15.15%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for RMD stock is "Buy." The 12-month stock price forecast is $213.67, which is an increase of 12.84% from the latest price.
News
ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be.
Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of weight-loss developments. It's an overreaction.
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.
Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling
Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have...
Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea
Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to inc...
ResMed Stock Is Sinking. Blame Lilly's Zepbound Trials for Sleep Apnea.
Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the ...
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep ...
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024 Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis...
3 Hot Stocks to Buy That Still Look Undervalued
#Morningstar #HotStocks #StockInvesting These top-performing stocks have beaten the market in 2024 yet appear to have more room to run. 00:00 Introduction 00:43 Moderna MRNA 01:27 Hasbro HAS 02:06 Re...
S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep Devices
Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher ...
ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.
The medical devices company beat expectations for its fiscal third quarter.
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices
ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended trading.
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, ...
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
ResMed announced the results of its 2024 Global Sleep Survey, uncovering a world in sleep crisis and encouraging people to discover their sleep superpowers
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed's Smallest Full-Face CPAP Mask
Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the ...
ResMed's New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assi...
Three-Stock Lunch: SoFi, Warner Bros. Discovery and ResMed
Boris Schlossberg, BK Asset Management, joins 'Power Lunch' to discuss SoFi, Warner Bros. Discovery and ResMed.
ResMed beats estimates on strong sleep apnea device sales
ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed says its masks to remain on market despite FDA classification
ResMed said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug Administration classified a recall of the product as most serious as their use could c...
US FDA identifies recall of ResMed's respiratory devices as most serious
The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday,...
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Heal...
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
ResMed's masks with magnets are safe when used in accordance with the updated Instructions for Use ResMed's masks with magnets are safe when used in accordance with the updated Instructions for Use